Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) announced an upcoming corporate update and release of third quarter 2025 financial results on Thursday, November 6, 2025.
The company said it will provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the quarter ended September 30, 2025, with details scheduled to be released before the market opens on November 6, 2025.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, QNRX declined 7.15%, reflecting a notable negative market reaction. Argus tracked a trough of -17.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $600K from the company's valuation, bringing the market cap to $8M at that time.
Data tracked by StockTitan Argus on the day of publication.
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q3 2025 financial results?
What will Quoin Pharmaceuticals cover in its November 6, 2025 corporate update for QNRX?
How can investors access Quoin Pharmaceuticals' Q3 2025 results for QNRX?
Does the November 6, 2025 announcement include a conference call or webcast for QNRX?
Which quarter do the November 6, 2025 financial highlights for QNRX cover?
Will Quoin Pharmaceuticals' November 6, 2025 release include clinical program updates for QNRX?
